- Home
- EFOR vs ACHV Comparison
EFOR vs ACHV Comparison
Compare EFOR & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EFOR | ACHV |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 2800 | N/A |
| Industry | Professional Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.1M | 618.0M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | EFOR | ACHV |
|---|---|---|
| Price | $18.23 | $6.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 1.1M | ★ 2.8M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.91 | $2.38 |
| 52 Week High | $19.69 | $7.11 |
Technical Indicators
Market Signals| Indicator | EFOR | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 53.04 | 55.34 |
| Support Level | $16.98 | $4.09 |
| Resistance Level | $19.30 | $7.11 |
| Average True Range (ATR) | 1.26 | 0.45 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 48.38 | 53.78 |
Price Performance
Historical ComparisonAbout EFOR Everforth Inc. Common Stock
Everforth Inc is a technology and digital engineering company that helps organizations adapt, innovate, and thrive in a world of constant change. It has six solution areas: AI & data, cloud and infrastructure, digital engineering, customer experience, cybersecurity, and enterprise platforms - accelerate time to value for commercial and federal clients.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.